Stock Analysis
Global Growth Companies With High Insider Ownership You Need To Know
Reviewed by Simply Wall St
As global markets navigate a period marked by declining consumer confidence and heightened policy risks, growth stocks have faced significant challenges, particularly within the technology sector. Amid this backdrop of economic uncertainty and mixed performance across major indices, investors are increasingly turning their attention to growth companies with substantial insider ownership—a factor often associated with strong alignment between management and shareholder interests.
Top 10 Growth Companies With High Insider Ownership Globally
Name | Insider Ownership | Earnings Growth |
Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
Vow (OB:VOW) | 12.9% | 120.9% |
Pharma Mar (BME:PHM) | 11.9% | 39.8% |
Laopu Gold (SEHK:6181) | 36.4% | 43.2% |
CD Projekt (WSE:CDR) | 29.7% | 39.4% |
Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 92.8% |
Elliptic Laboratories (OB:ELABS) | 22.6% | 89.9% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 125.9% |
Vuno (KOSDAQ:A338220) | 15.6% | 121.1% |
Fulin Precision (SZSE:300432) | 13.6% | 71% |
Let's uncover some gems from our specialized screener.
Keda Industrial Group (SHSE:600499)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Keda Industrial Group Co., Ltd. manufactures and sells building material machinery both in China and internationally, with a market cap of CN¥14.80 billion.
Operations: Keda Industrial Group generates its revenue from the manufacturing and sale of building material machinery across domestic and international markets.
Insider Ownership: 32.3%
Earnings Growth Forecast: 28.6% p.a.
Keda Industrial Group is experiencing strong growth prospects, with earnings expected to grow significantly at 28.6% annually, outpacing the Chinese market's 25.3%. Despite a lower profit margin of 6.9%, its revenue growth forecast of 14.5% remains robust compared to the broader market. The company recently completed a share buyback worth CNY 252.28 million, reflecting confidence in its value proposition with a P/E ratio of 19.4x, below the market average of 37.2x.
- Click here to discover the nuances of Keda Industrial Group with our detailed analytical future growth report.
- Our comprehensive valuation report raises the possibility that Keda Industrial Group is priced lower than what may be justified by its financials.
Nxera Pharma (TSE:4565)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Nxera Pharma Co., Ltd. is engaged in the development and sale of pharmaceutical products across Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom with a market cap of ¥76.24 billion.
Operations: The company's revenue primarily comes from its Pharmaceutical Business segment, which generated ¥28.84 billion.
Insider Ownership: 10.4%
Earnings Growth Forecast: 47.6% p.a.
Nxera Pharma is poised for growth, with earnings projected to rise 47.56% annually and revenue expected to grow at 9% per year, surpassing the JP market's average. Recent strategic agreements bolster its expansion in Asia-Pacific markets, including a partnership with Holling Bio-Pharma for daridorexant in Taiwan and Viatris for cenerimod in Japan. These deals include upfront payments and potential milestone revenues, enhancing Nxera's financial outlook without significant insider trading activity recently noted.
- Delve into the full analysis future growth report here for a deeper understanding of Nxera Pharma.
- According our valuation report, there's an indication that Nxera Pharma's share price might be on the expensive side.
Relo Group (TSE:8876)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Relo Group, Inc. provides property management services in Japan and has a market cap of ¥282.14 billion.
Operations: The company's revenue is derived from three main segments: Relocation Business at ¥99.73 billion, Fringe Benefit Business at ¥27.13 billion, and Tourism Business at ¥15.66 billion.
Insider Ownership: 29.0%
Earnings Growth Forecast: 16.1% p.a.
Relo Group is forecast to become profitable within three years, with earnings anticipated to grow at 16.12% annually, outpacing the JP market's average revenue growth of 4.2%. Despite slower revenue growth at 5.5% per year, Relo Group trades at a significant discount to its estimated fair value and boasts a high expected return on equity of 25.4%. Recent guidance projects JPY 140 billion in revenue and JPY 40 billion in profit for fiscal year ending March 2025.
- Take a closer look at Relo Group's potential here in our earnings growth report.
- Our comprehensive valuation report raises the possibility that Relo Group is priced higher than what may be justified by its financials.
Key Takeaways
- Navigate through the entire inventory of 878 Fast Growing Global Companies With High Insider Ownership here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Nxera Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:4565
Nxera Pharma
Develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom.